This study aims to understand THC pharmacology and the safety of cannabis vaping, including
the pharmacology and safety of co-administration of nicotine and THC. The study is designed
as a within-subjects single-blinded crossover study. Fourteen smokers of tobacco cigarettes
and cannabis will switch between three conditions, namely: (a) vaping cannabis leaf, (b)
vaping tobacco containing nicotine and (c) vaping a combination of cannabis leaf and tobacco
containing nicotine. All participants will vape each product with the PAX loose-leaf
vaporizer. The study will be conducted during three outpatient visits separated by at least
48 hours. The order of treatment (cannabis leaf, tobacco with nicotine, cannabis leaf &
tobacco with nicotine) will be counterbalanced between subjects. Subjects will be blinded to
the content of the vaporizer on the study day but will be told during screening that they
will vape cannabis alone, tobacco alone, and cannabis plus tobacco with nicotine.
Phase:
Phase 3
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
National Institute on Drug Abuse (NIDA) National Institutes of Health (NIH)